APMAP

DEM BioPharma Launches with $70 Million Financing

Retrieved on: 
星期四, 六月 23, 2022
Biotechnology, Pharmaceutical, Health, Oncology, CSO, Investment, Antibody, Phagocyte, Cancer, APMAP, DEM, Insight Partners, Scientific Advisory Group for Emergencies, Partner (business rank), Trillium, Genomics, HHMI, Whitehead Institute, National Academy of Sciences, Alta Partners, Â, CEO, EM, MIT, Coronavirus Scientific Advisory Board (Turkey), Chomp, CRISPR, Stanford University School of Medicine, Research, Science, Emerson Collective, Chemical substance, Dana–Farber Cancer Institute, Immunotherapy, Pfizer, Professor, Stanford University, DRS, Biomedical Research, Macrophage, Chemical engineering, Therapy, National academy, Phagocytosis, Neoplasm, Pharmaceutical industry, Vaccine, Interior design, Management, Genetics

DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor Longwood Fund and Alta Partners , with additional participation from Insight Partners , Pfizer Ventures , Astellas Venture Management , Emerson Collective , UTokyo Innovation Platform and Alexandria Venture Investments .

Key Points: 
  • DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor Longwood Fund and Alta Partners , with additional participation from Insight Partners , Pfizer Ventures , Astellas Venture Management , Emerson Collective , UTokyo Innovation Platform and Alexandria Venture Investments .
  • DEM Bio also announced the appointment of Jan Skvarka, former CEO of Trillium Therapeutics (acquired by Pfizer for $2.22 billion in November 2021), as Executive Chairman.
  • DEM Bios founders discovered a scalable approach to systematically unlock the potential of innate immune system checkpoints, noted Dr. Westphal.
  • The CHoMP platform has identified a number of promising new DEM/EM signals, including the novel DEM pathway APMAP.